{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:52:45Z","timestamp":1789761165892,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"21","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Barakat Foundation"},{"name":"Alborz Darou"},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C20\/A5860"],"award-info":[{"award-number":["C20\/A5860"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"crossref","award":["81\/15"],"award-info":[{"award-number":["81\/15"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]},{"name":"IARC"},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ARC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Individuals with non-alcoholic steatohepatitis or elevated liver enzymes have increased cardiovascular mortality but are often excluded from prevention trials. We investigated the effectiveness of fixed-dose combination therapy for the prevention of major cardiovascular events (MCVE) among individuals with and without presumed non-alcoholic steatohepatitis (pNASH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Two thousand four hundred participants over 50 were randomized into the intervention and control groups. Consent was obtained post-randomization. Consenting participants in the intervention group were given a pill containing aspirin, atorvastatin, hydrochlorothiazide, and valsartan (polypill). Participants were followed for 5 years. Presumed non-alcoholic steatohepatitis was diagnosed by ultrasonography and elevated liver enzymes. The primary outcome was MCVE. ClinicalTrials.gov: NCT01245608. Among the originally randomized population, 138 of 1249 in the intervention group (11.0%) and 137 of 1017 controls (13.5%) had MCVE during the 5-year follow-up [unadjusted risk ratio (RR) 0.83, 95% confidence interval (CI) 0.66\u20131.03]. Of the 1508 participants who consented to additional measurements and treatment, 63 of 787 (8.0%) intervention group participants and 86 of 721 (11.9%) controls had MCVE (adjusted RR 0.61, 95% CI 0.44\u20130.83). Although the adjusted relative risk of MCVE in participants with pNASH (0.35, 95% CI 0.17\u20130.74) was under half that for participants without pNASH (0.73, 95% CI 0.49\u20131.00), the difference did not reach statistical significance. There was no change in liver enzymes in participants taking polypill but among those with pNASH, there was a significant decrease after 60 months of follow-up (intragroup \u221212.0 IU\/L, 95% CI \u221214.2 to \u22129.6).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among patients consenting to receive fixed-dose combination therapy, polypill is safe and effective for the prevention of MCVE, even among participants with fatty liver and increased liver enzymes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab919","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T20:10:04Z","timestamp":1640808604000},"page":"2023-2033","source":"Crossref","is-referenced-by-count":25,"title":["Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-6723","authenticated-orcid":false,"given":"Shahin","family":"Merat","sequence":"first","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran"},{"name":"Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran 1411713135, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Jafari","sequence":"additional","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran"},{"name":"Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences , Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Radmard","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences , Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Khoshnia","sequence":"additional","affiliation":[{"name":"Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences , Gorgan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sharafkhah","sequence":"additional","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Nateghi Baygi","sequence":"additional","affiliation":[{"name":"Research and Development Department, Alborz-Darou Pharmaceutical Co. , Ghazvin, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-5214","authenticated-orcid":false,"given":"Tom","family":"Marshall","sequence":"additional","affiliation":[{"name":"School of Health and Population Sciences, University of Birmingham , Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolfazl","family":"Shiravi Khuzani","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences , Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1516-1857","authenticated-orcid":false,"given":"Kar Keung","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Health and Population Sciences, University of Birmingham , Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4566-3628","authenticated-orcid":false,"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran"},{"name":"Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran 1411713135, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-6335","authenticated-orcid":false,"given":"Reza","family":"Malekzadeh","sequence":"additional","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran"},{"name":"Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Shariati Hospital, Tehran 1411713135, Iran"},{"name":"Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences , Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"2022102603272820400_ehab919-B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022102603272820400_ehab919-B2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"2022102603272820400_ehab919-B3","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"2022102603272820400_ehab919-B4","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jacc.2016.01.070","article-title":"Nonalcoholic fatty liver disease and incident cardiac events: the Multi-Ethnic Study of Atherosclerosis","volume":"67","author":"Zeb","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102603272820400_ehab919-B5","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"2022102603272820400_ehab919-B6","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-12-3","article-title":"A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization","volume":"12","author":"Soliman","year":"2011","journal-title":"Trials"},{"key":"2022102603272820400_ehab919-B7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022102603272820400_ehab919-B8","doi-asserted-by":"crossref","first-page":"1179552218787502","DOI":"10.1177\/1179552218787502","article-title":"An evidence-based review of statin use in patients with nonalcoholic fatty liver disease","volume":"11","author":"Sigler","year":"2018","journal-title":"Clin Med Insights Gastroenterol"},{"key":"2022102603272820400_ehab919-B9","doi-asserted-by":"crossref","first-page":"2776.e4","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022102603272820400_ehab919-B10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/liv.12611","article-title":"Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease","volume":"35","author":"Goh","year":"2015","journal-title":"Liver Int"},{"key":"2022102603272820400_ehab919-B11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","article-title":"Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial","volume":"394","author":"Roshandel","year":"2019","journal-title":"Lancet"},{"key":"2022102603272820400_ehab919-B12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.bjc.6602249","article-title":"Golestan cohort study of oesophageal cancer: feasibility and first results","volume":"92","author":"Pourshams","year":"2005","journal-title":"Br J Cancer"},{"key":"2022102603272820400_ehab919-B13","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJM197905313002203","article-title":"A new design for randomized clinical trials","volume":"300","author":"Zelen","year":"1979","journal-title":"N Engl J Med"},{"key":"2022102603272820400_ehab919-B14","first-page":"515","article-title":"PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran\u2014Liver)\u2014study protocol","volume":"18","author":"Merat","year":"2015","journal-title":"Arch Iran Med"},{"key":"2022102603272820400_ehab919-B15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102603272820400_ehab919-B16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102603272820400_ehab919-B17","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102603272820400_ehab919-B18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0149-2918(98)80107-0","article-title":"Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker","volume":"20","author":"Pool","year":"1998","journal-title":"Clin Ther"},{"key":"2022102603272820400_ehab919-B19","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1097\/HJH.0000000000001836","article-title":"Salt intake among Iranian population: the first national report on salt intake in Iran","volume":"36","author":"Rezaei","year":"2018","journal-title":"J Hypertens"},{"key":"2022102603272820400_ehab919-B20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1570161115666170621082910","article-title":"Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk","volume":"16","author":"Athyros","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"2022102603272820400_ehab919-B21","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.2174\/1381612825666190117114305","article-title":"The role of statins in the management of nonalcoholic fatty liver disease","volume":"24","author":"Doumas","year":"2018","journal-title":"Curr Pharm Des"},{"key":"2022102603272820400_ehab919-B22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"2022102603272820400_ehab919-B23","doi-asserted-by":"crossref","first-page":"g3318","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"key":"2022102603272820400_ehab919-B24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13643-019-1014-8","article-title":"Medication adherence influencing factors\u2014an (updated) overview of systematic reviews","volume":"8","author":"Gast","year":"2019","journal-title":"Syst Rev"},{"key":"2022102603272820400_ehab919-B25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2010.01.008","article-title":"Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations","volume":"52","author":"Lee","year":"2010","journal-title":"J Hepatol"},{"key":"2022102603272820400_ehab919-B26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/gast.2003.50032","article-title":"Defining nonalcoholic fatty liver disease: implications for epidemiologic studies","volume":"124","author":"Clark","year":"2003","journal-title":"Gastroenterology"},{"key":"2022102603272820400_ehab919-B27","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"key":"2022102603272820400_ehab919-B28","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3748\/wjg.14.2867","article-title":"Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes","volume":"14","author":"Jamali","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2022102603272820400_ehab919-B29","first-page":"14","article-title":"Prevalence of nonalcoholic steatohepatitis in Iran: a population based study","volume":"2","author":"Sohrabpour","year":"2010","journal-title":"Middle East J Dig Dis"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/21\/2023\/46630986\/ehab919.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/21\/2023\/46630986\/ehab919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:28:10Z","timestamp":1666754890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/21\/2023\/6511856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":29,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,1,20]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab919","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,1,20]]}}}